Search results for "Mabs" in Articles / App Notes
Article
Intensified Chromatography Strategies
The blockbuster drug era is over and drug manufacturers are now striving for a more diversified portfolio by targeting a greater number of monoclonal antibody (mAb) products at lower production volu…
Article
2019 HTPD Conference Is Announced. What Happened Last Time?
HTPD 2019 will cover process development spanning upstream through downstream processing for both mAbs, Ab-like molecules as well as novel biomolecules. Sessions will also include integrated P…
Article
Ion Exchange Chromatography: Introducing New Capto™ HiRes Columns
These new-generation columns are the latest IEX columns delivering the highest resolution, for laboratory-scale purification.
• Designed for the preparation of highly pure proteins and for prote…
Article
Getting a Handle on Biopharma’s Most Critical Quality Attributes and Quality Control
While the multiple attributes method gains ground and traditional lab methods improve, broad efforts are underway to determine biopharmaceuticals’ most significant critical quality attributes and en…
Article
Analytical SEC: How Does Back Pressure Relate to Resolution?
High resolution in HPLC is not achieved by applying back pressure to the column. Let’s straighten out what really helps you achieve high-resolution analytical SEC data.
Read paper
Article
Protein Analysis with Size Exclusion Chromatography
Size exclusion chromatography (SEC) is widely used in several different analytical applications from basic research to quality control of biotherapeutics. This white paper presents fundamentals abou…
Article
Bispecific Antibody Purification: Insights and Case Studies
New modalities, like bispecific antibodies, present unique challenges compared to mAb production. For purification, there’s not just one right answer to which strategy to use. Here are some industry…
Article
Single-Step, Protein A Chromatography Process for Bispecific Antibodies in Early Screening
MabSelect™ PrismA protein A resin was selected for the capture step. Most fragments could be removed as early as the capture step using gradient elution from pH 5 to 3.5, without the need for addition…
Article
A Plastic Pipeline for Commercial Bioprocessing?
A Plastic Pipeline for Commercial Bioprocessing?
The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.
By Rita C. Peters
…
Article
Optimizing Late-Stage and Commercial Cell-Culture Processes
In the early 1990s, cell titers for monoclonal antibodies (mAbs) were in the range of 50–100 mg/L, notes Dr. Andy Racher, associate director future technologies, Lonza Pharma & Biotech. Today, however…